The layoffs, which will begin April 5, come after a string of setbacks at the San Francisco-based biotech.
AbbVie purchased Stemcentrx in 2016 for a cancer drug candidate, Rova-T. However, the drugmaker has encountered a series of setbacks with Rova-T, including a failed late-stage trial. In January, AbbVie opted to take a $4 billion impairment charge related to its 2016 acquisition of Stemcentrx.
An AbbVie spokesperson didn’t return the Business Journal‘s request for comment about the layoffs.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
